Screens for small molecule treatments have been instigated, including for Tangier disease (ABCA1), gout (ABCG2), Stargardt eye disease (ABCA4), progressive familial intrahepatic cholestasis type 2 (ABCB11) (Allikmets et al, 1997; Strautnieks et al, 1998; Rust et al, 1999; Woodward et al, 2009), and congenital hyperinsulinemia (Chen et al, 2013). This evidence concerns the gene ABCG2 and gout.